Cyberonics reneged on its "Lifetime Reimbursement Guarantee". Click on the image to learn how you can help...
Showing posts with label transcutaneous Vagus Nerve Stimulation. Show all posts
Showing posts with label transcutaneous Vagus Nerve Stimulation. Show all posts

Thursday, August 23, 2012

Cerbomed GmbH: transcutaneous Vagus Nerve Stimulation for pain relief

Cerbomed GmbH: transcutaneous Vagus Nerve Stimulation for pain relief

Published: August 23, 2012

Read more here: http://www.heraldonline.com/2012/08/23/4208412/cerbomed-gmbh-transcutaneous-vagus.html#storylink=cpy


— The medical device company cerbomed GmbH from Erlangen, Germany has received the European clearance (CE mark) for the application of transcutaneous Vagus Nerve Stimulation (t-VNS) in pain relief therapy.

Pain-relieving effect of t-VNS
A randomized study on pain processing was conducted in cooperation with the university of Regensburg in 2011. With t-VNS, there was a significant reduction of perceived mechanical pain in healthy volunteers (Busch et al., Brain Stimulation, in press).

In a second randomized controlled study, pain processing in the right and left hand was examined on 49 healthy volunteers on three different days. The effect of a dextral t-VNS after stimulation of the left ear was also examined for the first time. In both cases, t-VNS reduced pain perception following mechanical stimuli significantly.

“The current results and literature data form the foundation of the clinical study on the effect of t-VNS in chronic migraine treatment. It is conducted by the Headache Center of the Neurological Department at the Großhadern Hospital in Munich”, explains Prof. Dr. Jens Ellrich, Chief Medical Officer of cerbomed GmbH. The randomized controlled study is examining the efficacy of t-VNS on 98 patients suffering from chronic migraine.

From August 27th to 31st, cerbomed will be presenting t-VNS to an expert audience at the 14th World Congress on Pain in Milan, which is organized by the International Association for the Study of Pain.

About t-VNS
Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult to treat neurological and psychiatric diseases. The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.

About cerbomed
Cerbomed is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.

Find out more about cerbomed at www.cerbomed.com

http://www.heraldonline.com/2012/08/23/4208412/cerbomed-gmbh-transcutaneous-vagus.html

Read more here: http://www.heraldonline.com/2012/08/23/4208412/cerbomed-gmbh-transcutaneous-vagus.html#storylink=cpy

Wednesday, August 15, 2012

Transcutaneous Vagus Nerve Stimulation: Retrospective Assessment of Cardiac Safety in a Pilot Study.

2012;3:70. Epub 2012 Aug 7.

Transcutaneous Vagus Nerve Stimulation: Retrospective Assessment of Cardiac Safety in a Pilot Study.

Source

Department of Psychiatry and Psychotherapy, University of Regensburg Regensburg, Germany.

Abstract

Background: Vagus nerve stimulation has been successfully used as a treatment strategy for epilepsy and affective disorders for years. Transcutaneous vagus nerve stimulation (tVNS) is a new non-invasive method to stimulate the vagus nerve, which has been shown to modulate neuronal activity in distinct brain areas. Objectives: Here we report effects of tVNS on cardiac function from a pilot study, which was conducted to evaluate the feasibility and safety of tVNS for the treatment of chronic tinnitus. Methods: Twenty-four patients with chronic tinnitus underwent treatment with tVNS over 3-10 weeks in an open single-armed pilot study. Safety criteria and practical usability of the neurostimulating device were to investigate by clinical examination and electrocardiography at baseline and at several visits during and after tVNS treatment (week 2, 4, 8, 16, and 24). Results: Two adverse cardiac events (one classified as a severe adverse event) were registered but considered very unlikely to have been caused by the tVNS device. Retrospective analyses of electrocardiographic parameters revealed a trend toward shortening of the QRS complex after tVNS. Conclusion: To our knowledge this is one of the first studies investigating feasibility and safety of tVNS in a clinical sample. In those subjects with no known pre-existing cardiac pathology, preliminary data do not indicate arrhythmic effects of tVNS.
PMID:
22891061
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22891061

Related citations in PubMed


See reviews...See all...

Friday, March 9, 2012

A renewed web presence for cerbomed GmbH

A renewed web presence for cerbomed GmbH

Pressemitteilung von: cerbomed GmbH
(openPR) - ERLANGEN, Germany, March 8th, 2012 – The German medical device company cerbomed GmbH is re-launching its web site. At www.cerbomed.com patients and their families, as well as doctors, and medical specialists can access tailored information on transcutaneous Vagus Nerve Stimulation (t-VNS), using the device NEMOS. The new therapy alternative for difficult-to-treat epilepsies and depression will be available in Germany in summer 2012.

The new web-presence marks cerbomed as a provider of innovative therapies.

About t-VNS
Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult to treat neurological and psychiatric diseases. The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.

About NEMOS
For t-VNS cerbomed developed and patented a special stimulator and a dedicated ear electrode. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With the transcutaneous vagus nerve stimulator NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.

The German market entry for NEMOS is planned for the third quarter of 2012. NEMOS will then be available for patients suffering from hard-to-treat epilepsies and depression.

Cerbomed GmbH is an innovative medical device company that concentrates on researching, developing and producing new technologies and products for neuromodulation. The company’s focus is on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.

In 2011 cerbomed received the European clearance (CE mark) for the transcutaneous vagus nerve stimulator NEMOS. In early 2012 two more clinical studies will be starting regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.

cerbomed GmbH
Dr. Martin Hyca, Director Marketing
Henkestrasse 91
DE-91052 Erlangen
+49 9131 9202 76 30
martin.hyca@cerbomed.com
http://www.openPR.com/news/213637/A-renewed-web-presence-for-cerbomed-GmbH.html

Tuesday, February 21, 2012

Expertise in epilepsy treatment: Prof. Dr. med. Hajo Hamer reinforces the scientific advisory board of cerbomed GmbH

Expertise in epilepsy treatment: Prof. Dr. med. Hajo Hamer reinforces the scientific advisory board of cerbomed GmbH

Pressemitteilung von: cerbomed GmbH
(openPR) - ERLANGEN, Germany, 21.02.2012 – In Prof. Dr. Hajo Hamer the medical device company cerbomed GmbH gains a renowned expert in epileptology for its scientific advisory board.

Prof. Dr. Hamer will support cerbomed GmbH in carrying out an international multi-center study to treat drug-resistant epilepsy, using transcutaneous Vagus Nerve Stimulation (t-VNS).

Since April 1st, 2011 Prof. Dr. Hamer has been the new head of the Epilepsy Center at the University Hospital, Erlangen, and a senior physician in the neurological clinic. The emphases of his research are on the investigation of inflammable changes in epilepsy, and on optimizing the care of patients with epilepsy, among others. As part of the interdisciplinary team of the Epilepsy Center Erlangen, he is responsible for treating around 3,000 patients. One of the main emphases of his clinical work is the therapy of hard-to-treat epilepsies.

"In more than 30 percent of all epilepsy patients undergoing an anticonvulsive therapy there is no significant decrease in the frequency of seizures. It is therefore important to explore new forms of therapy. Transcutaneous Vagus Nerve Stimulation could represent a new, non-invasive therapy option for treating drug-resistant epilepsy", says Prof. Dr. Hamer.

"We are very pleased that Prof. Dr. Hamer is supporting us in conducting the multi-center study, which will examine the effectiveness and safety of t-VNS in 70 patients", explains Prof. Dr. Jens Ellrich, Chief Medical Officer at cerbomed GmbH.

Cerbomed GmbH will introduce the t-VNS therapy at the 51st annual conference of the German Society for Epileptology e.V. in Stuttgart, between February 29th and March 3rd, 2012.

About NEMOS
Transcutaneous Vagus Nerve Stimulation with NEMOS uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses. For t-VNS cerbomed developed and patented a special stimulator and a dedicated ear electrode. The stimulator, which is connected with the ear electrode, sends out the electrical impulses.

The t-VNS therapy is addressed to patients suffering from various difficult to treat neurological and psychiatric diseases. With NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.

The German market entry for NEMOS is planned for the third quarter of 2012. NEMOS will then be available for patients suffering from hard-to-treat epilepsies and depressions.

Cerbomed GmbH is an innovative medical device company that concentrates on researching, developing and producing new technologies and products for neuromodulation. The company’s focus is on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard to treat neurological and psychiatric illnesses.

In March 2010 cerbomed received the European clearance (CE mark) for the transcutaneous vagus nerve stimulator NEMOS. In early 2012 two clinical studies will be starting regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.

cerbomed GmbH
Dr. Martin Hyca, Director Marketing
Henkestrasse 91
DE-91052 Erlangen
+49 9131 9202 76 30
martin.hyca@cerbomed.com

http://www.openpr.com/news/211670/Expertise-in-epilepsy-treatment-Prof-Dr-med-Hajo-Hamer-reinforces-the-scientific-advisory-board-of-cerbomed-GmbH.html